Like the other NLRP3-targeted drugs mentioned above, colchicine seemed to have minimal effects in community-treated patients without a mandatory diagnostic test but led to a lower rate of the composite of death or admission to the hospital among those with PCR-confirmed COVID-19.50 This evidence concerns the gene NLRP3 and COVID-19.